Multigene panel testing should be considered for all African-American women with triple-negative breast cancer regardless of their age or cancer history.
A retrospective review found that the presence of variants of uncertain significance on multigene panel testing does not increase the rate of contralateral prophylactic mastectomies.
Hereditary syndromes that increase the risk of breast cancer are not common, but it is critical to recognize and manage them appropriately.
With increasing genetic insights into hereditary breast cancer, clinicians must decide which of a variety of diagnostic and prognostic genetic test they should offer patients and their families. Holly Pederson, MD, Director of Cleveland Clinic’s Medical Breast and Hereditary High-Risk programs, discusses the choices.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic offers two specialized clinics to provide tailored care to meet the specific needs of patients with breast cancer – those at high risk due to heredity and those who are younger at initial diagnosis.